

An algorithm for the evaluation and management of red, yellow, and green zone patients during a botulism mass casualty incident
Abstract
Keywords
References
Centers for Disease Control and Prevention: Bioterrorism Agents/Diseases, A to Z by Category. Available at www.bt.cdc.gov/agent/agentlist-category.asp. Accessed June 3, 2009.
Arnon SS, Schlecter R, Ingelsby D, et al.: Botulinum toxin as a biological weapon. JAMA. 2001; 285: 1059-1070.
Dembek ZF, Smith LA, Rusnak JM: Botulism: Cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med Public Health Prep. 2007; 1(2): 122-134.
Villar RG, Elliot SP, Davenport KM: Botulism: The many faces of botulinum toxin and its potential for bioterrorism. Infect Dis Clin North Am. 2006; 20(2): 313-327.
Koirala J, Basner S: Botulism, botulinum toxin, and bioterrorism: Review and update. Infect Med. 2004; 21: 284-290.
Botulism: Current, comprehensive information on pathogenesis, microbiology, epidemiology, diagnosis, and treatment. Available at http://www.cidrap.umn.edu/cidrap/content/bt/botulism/biofacts/botulismfactsheet.html. Accessed June 7, 2009.
Taillac PP, Kim J: CBRNE – Botulism.Available at http://emedicine.medscape.com/article/829125-overview. Accessed June 7, 2009.
Stankovic C, Mahajan P,Ye H, et al.: Bioterrorism: Evaluating the preparedness of pediatricians in Michigan. Pediatr Emerg Care. 2009; 25(2): 88-92.
Chen FM, Hickner J, Fink KS, et al.: On the front lines: Family physicians’ preparedness for bioterrorism. J Fam Pract. 2002; 51(9): 745-750.
Alexander GC, Larkin GL,Wynia MK: Physicians’ preparedness for bioterrorism and other public health priorities. Acad Emerg Med. 2006; 13(11): 1238-1241.
Iserson KV, Heine CE, Larkin GL, et al.: Fight or flight: The ethics of emergency physician disaster response. Ann Emerg Med. 2008; 51: 345-353.
Lerner EB, Schwartz RB, Coule PL, et al.: Mass casualty triage: An evaluation of the data and development of a proposed guideline. Disast Med Pub Health Prep. 2008; 2(Suppl 1): S25-S34.
Patocka J, Splino M, Merka V: Botulism and bioterrorism: How serious is it? Acta Medica *Hradec Kralove. 2005; 48(1): 23-28.
Bedlak RS, Sanders DB: How to handle myasthenic crisis. Postgrad Med. 2000; 107: 211-222.
Tseng BS, Markowitz JA: Guillain-Barrè syndrome in childhood. Available at http://emedicine.medscape.com/article/1180594-overview. Accessed June 7, 2009.
Green DM:Weakness in the ICU: Guillain-Barrè, myasthenia gravis, and critical illness polyneuropathy/myopathy. Neurologist. 2005; 11: 338-347.
Mehta S: Neuromuscular disease causing acute respiratory failure. Resp Care. 2006; 51: 1016-1021.
Fulgham JR,Wijdicks EFM: Guillain-Barrè syndrome. Crit Care Clin. 1997; 13(1): 1-15.
Orenstein DM, Holt LS, Rebovich P, et al.: Measuring ease of breathing in young patients with cystic fibrosis. Ped Pulmon. 2002; 34(6): 473-477.
Jain VK, Behari S: Management of atlanto-axial dislocation: Some lessons learned. Neurol India. 2002; 50(4): 386-397.
Yavagal DR, Mayer SA: Respiratory complications of rapidly progressive neuromuscular syndromes: Guillain-Barrè syndrome and myasthenia gravis. Semin Respir Crit Care Med. 2002; 23(2): 221-229.
Van Rynen JL, Rega PP, Budd C, et al.: The use of negative inspiratory force by ed personnel to monitor respiratory deterioration in the event of a botulism-induced MCI. J Emerg Nurs. 2009; 35(2): 114-117.
Rega P, Bork C, Burkholder-Allen K, et al.: The single-breathcount test as an adjunct in triage during a botulism mass-casualty incident. Prehosp Disaster Med. 2009 (in press).
Van Rynen JL, Rega PP, Budd C, et al.: The use of negative inspiratory force by ed personnel to monitor respiratory deterioration in the event of a botulism-induced MCI. J Emerg Nurs. 2009; 35(2): 114-117.
Mace SE: Challenges and advances in intubation: Airway evaluation and controversies with intubation. Emerg Med Clin N Am. 2008; 26: 977-1000.
Botulism Antitoxin Bivalent (Equine) Types A and B Product Insert. Avilable at http://botulismtoolkit.com/wp-content/media/botulismab.pdf. Accessed July 17, 2009.
BabyBIG®, Botulism immune globulin intravenous (human) (BIG-IV) product insert (2003). Available at http://botulismtoolkit.com/?page_id=56. Accessed July 17, 2009.
Clinical pathway: Botulism. Center for Infectious Disease Research and Policy. Available at www.cidrap.umn.edu/cidrap/files/19/botulism_clinical_pathway.pdf. Accessed July 17, 2009.
Botulism. Infectious Disease Epidemiology Section, Office of Public Health, Louisiana Department of Health and Hospitals. Revised April 20, 2009.
DOI: https://doi.org/10.5055/ajdm.2009.0030
Refbacks
- There are currently no refbacks.